Chinese Medical Sciences Journal ›› 2019, Vol. 34 ›› Issue (3): 184-193.doi: 10.24920/003558

• 论著 • 上一篇    下一篇



  1. 1 中南大学湘雅医院肿瘤科,长沙 410008
    2 中南大学湘雅医院耳鼻咽喉头颈外科,长沙 410008
    3 中南大学湘雅医院药剂科,长沙 410008
  • 收稿日期:2019-07-02 出版日期:2019-09-30 发布日期:2019-07-02
  • 通讯作者: 刘铮铮,田勇泉;

Downregulation of iASPP Expression Suppresses Proliferation, Invasion and Increases Chemosensitivity to Paclitaxel of Head and Neck Squamous Cell Carcinoma In Vitro

Liu Zhengzheng1,*(),Kuang Weilu1,Zeng Wenjing3,Xiao Jianyun2,Tian Yongquan2,*()   

  1. 1 Department of Oncology, , Xiangya Hospital, Central South University, Changsha 410008, China
    2 Department of Pharmacy, , Xiangya Hospital, Central South University, Changsha 410008, China
    3 Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha 410008, China
  • Received:2019-07-02 Published:2019-09-30 Online:2019-07-02
  • Contact: Liu Zhengzheng,Tian Yongquan;


目的 我们前期的研究表明:iASPP在人头颈鳞状细胞癌(HNSCC)中表达升高,且iASPP过表达与HNSCC的恶性生物学行为及不良预后密切相关。本研究旨在探讨下调iASPP表达对体外培养的HNSCC细胞系Tu686增殖和侵袭的影响。

方法 采用慢病毒介导的特异性iASPP shRNA和control shRNA分别转染Tu686细胞,转染后的细胞分别作为shRNA-iASPP组和shRNA-NC组;未转染的Tu686细胞为CON组。采用CCK-8法、流式细胞术、Transwell侵袭实验检测下调iASPP基因表达对Tu686细胞的影响。

结果 CCK-8结果显示:shRNA-iASPP组细胞在转染后72 h(F=32.459,P=0.000)、96 h(F=51.407, P=0.000)、120 h(F=35.125,P=0.000)的增殖明显低于shRNA-NC组和CON组。流式细胞术结果显示:shRNA-iASPP组细胞凋亡率为9.42%±0.39%(F=299.490,P=0.000),明显高于CON组(2.80%±0.42%)和shRNA-NC组(3.18%±0.28%)。shRNA-iASPP组中处于G0/G1期的细胞比例为74.65%±1.09%(F=388.901,P=0.000),明显高于CON组(55.19%±1.02%)和shRNA-NC组(54.62%±0.88%)。侵袭实验显示:shRNA-iASPP组的侵袭细胞数目为56±4,比CON组(111±3)和shRNA-NC组(105±8)显著降低(F=84.965,P=0.000)。CCK-8实验结果表明:在紫杉醇作用下,shRNA-iASPP组细胞的存活率显著低于CON组和shRNA-NC组(F=634.841,P=0.000)。

结论 iASPP在HNSCC的发生、发展中起重要作用,有可能成为增强头颈鳞状细胞癌对紫杉醇化疗敏感性的有效分子治疗靶点。

关键词: 头颈鳞状细胞癌, iASPP, 化疗敏感性, 紫杉醇


Objective Our previous study has revealed that iASPP is elevated in human head and neck squamous cell carcinoma (HNSCC) and iASPP overexpression signifcantly correlates with tumor malignant progression and poor survival of HNSCC. This study investigated the function of iASPP playing in proliferation and invasion of HNSCC in vitro.

Methods HNSCC cell line Tu686 transfected with Lentiviral vector-mediated iASPP-specific shRNA and control shRNA were named the shRNA-iASPP group and shRNA-NC group, respectively. The non-infected Tu686 cells were named the CON group. CCK-8 assay, flow cytometry, transwell invasion assay were performed to detect the effects of iASPP inhibition in vitro.

Results Our results demonstrated that the proliferation of shRNA-iASPP cells at the time of 72 h (F=32.459, P=0.000), 96 h (F=51.407, P=0.000), 120 h (F=35.125, P=0.000) post-transfection, was significantly lower than that of shRNA-NC cells and CON cells. The apoptosis ratio of shRNA-iASPP cells was 9.42% ± 0.39% (F=299.490, P=0.000), which was significantly higher than that of CON cells (2.80% ± 0.42%) and shRNA-NC cells (3.18% ± 0.28%). The percentage of shRNA-iASPP cells in G0/G1 phase was 74.65% ± 1.09% (F=388.901, P=0.000), which was strikingly increased, compared with that of CON cells (55.19% ± 1.02%) and shRNA-NC cells (54.62% ± 0.88%). The number of invading cells was 56 ± 4 in the shRNA-iASPP group (F=84.965, P=0.000), which decreased significantly, compared with the CON group (111 ± 3) and the shRNA-NC group (105 ± 8). The survival rate of shRNA-iASPP cells administrated with paclitaxel was highly decreased, compared with CON cells and shRNA-NC cells (F=634.841, P=0.000).

Conclusion These results suggest iASPP may play an important role in progression and aggressive behavior of HNSCC and may be an efficient chemotherapeutic target for the treatment of HNSCC.

Key words: human head and neck squamous cell carcinoma, iASPP, chemosensitivity, paclitaxel

Copyright © 2018 Chinese Academy of Medical Sciences. All right reserved.
京公安备110402430088 京ICP备06002729号-1  Powered by Magtech.

Supervised by National Health & Family Plan Commission of PRC

9 Dongdan Santiao, Dongcheng district, Beijing, 100730 China

Tel: 86-10-65105897  Fax:86-10-65133074 


Copyright © 2018 Chinese Academy of Medical Sciences

All right reserved.

京公安备110402430088  京ICP备06002729号-1